论文部分内容阅读
本文通过分析我国创新药品可获得性现状与影响因素,在理论上分析基础上,比较左乙拉西坦(Keppra)在中美上市准入情况与数据保护强度,探究药品数据保护与创新药品可获得性之间的关系。药品数据保护制度可有效促进国外创新药品尽快进入我国市场。建议我国尽快完善药品数据保护制度,以期提高我国新药可获得性,保障公众健康福利。
Based on the theoretical analysis, the article compares Keppra’s market access and data protection intensity between China and the United States, and explores the relationship between drug data protection and innovative drugs The relationship between acquired. Drug data protection system can effectively promote foreign innovative drugs into our market as soon as possible. It is suggested that China should improve its drug data protection system as soon as possible so as to improve the availability of new drugs in our country and protect public health and welfare.